Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 18;9(1):82.
doi: 10.3390/antiox9010082.

Mitoprotective Clinical Strategies in Type 2 Diabetes and Fanconi Anemia Patients: Suggestions for Clinical Management of Mitochondrial Dysfunction

Giovanni Pagano  1 , Federico V Pallardó  2 , Beatriz Porto  3 , Maria Rosa Fittipaldi  4 , Alex Lyakhovich  5   6 , Marco Trifuoggi  1
Affiliations
Review

Mitoprotective Clinical Strategies in Type 2 Diabetes and Fanconi Anemia Patients: Suggestions for Clinical Management of Mitochondrial Dysfunction

Giovanni Pagano et al. Antioxidants (Basel). .

Abstract

Oxidative stress (OS) and mitochondrial dysfunction (MDF) occur in a number of disorders, and several clinical studies have attempted to counteract OS and MDF by providing adjuvant treatments against disease progression. The present review is aimed at focusing on two apparently distant diseases, namely type 2 diabetes (T2D) and a rare genetic disease, Fanconi anemia (FA). The pathogenetic links between T2D and FA include the high T2D prevalence among FA patients and the recognized evidence for OS and MDF in both disorders. This latter phenotypic/pathogenetic feature-namely MDF-may be regarded as a mechanistic ground both accounting for the clinical outcomes in both diseases, and as a premise to clinical studies aimed at counteracting MDF. In the case for T2D, the working hypothesis is raised of evaluating any in vivo decrease of mitochondrial cofactors, or mitochondrial nutrients (MNs) such as α-lipoic acid, coenzyme Q10, and l-carnitine, with possibly combined MN-based treatments. As for FA, the established knowledge of MDF, as yet only obtained from in vitro or molecular studies, prompts the requirement to ascertain in vivo MDF, and to design clinical studies aimed at utilizing MNs toward mitigating or delaying FA's clinical progression. Altogether, this paper may contribute to building hypotheses for clinical studies in a number of OS/MDF-related diseases.

Keywords: Fanconi anemia; mitochondrial dysfunction; mitochondrial nutrients; oxidative stress; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Luft R. The development of mitochondrial medicine. Proc. Natl. Acad. Sci. USA. 1994;91:8731–8738. doi: 10.1073/pnas.91.19.8731. - DOI - PMC - PubMed
    1. Pagano G., Talamanca A.A., Castello G., Cordero M.D., d’Ischia M., Gadaleta M.N., Pallardó F.V., Petrović S., Tiano L., Zatterale A. Oxidative stress and mitochondrial dysfunction across broad-ranging pathologies: Toward a rational design of chemoprevention strategies by means of mitochondrial nutrients. Oxid. Med. Cell. Longev. 2014;2014 doi: 10.1155/2014/541230. - DOI - PMC - PubMed
    1. Picard M., Wallace D.C., Burelle Y. The rise of mitochondria in medicine. Mitochondrion. 2016;30:105–116. doi: 10.1016/j.mito.2016.07.003. - DOI - PMC - PubMed
    1. Cipak Gasparovic A., Zarkovic N., Zarkovic K., Semen K., Kaminskyy D., Yelisyeyeva O., Bottari S.P. Biomarkers of oxidative and nitro-oxidative stress: Conventional and novel approaches. Br. J. Pharmacol. 2017;174:1771–1783. doi: 10.1111/bph.13673. - DOI - PMC - PubMed
    1. Pinti M.V., Fink G.K., Hathaway Q.A., Durr A.J., Kunovac A., Hollander J.M. Mitochondrial dysfunction in type 2 diabetes mellitus: An organ-based analysis. Am. J. Physiol. Endocrinol. Metab. 2019;316:E268–E285. doi: 10.1152/ajpendo.00314.2018. - DOI - PMC - PubMed